전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved157 programs
CGTLimited DatastaleMillennium Pharmaceuticals, Inc.Phase 2

ENK Cell Infusion (ENK Cell Infusion)

Asymptomatic Multiple Myeloma · Asymptomatic Multiple Myeloma

#AsymptomaticMultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 2Status Active
AntibodyLimited DatastalePfizerPhase 2

Elranatamab-bcmm (Elranatamab-bcmm)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Pfizer
Trials 2Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Active
AntibodyLimited DatastaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Relapsedand+2
Trials 2Status Active
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-daratumumab PET/CT)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Janssen
Trials 1Status Active
CGTLimited DatastaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CS1 cCAR T cells (BCMA-CS1 cCAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.50 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.75 x10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCells & Genes Biotech (Shanghai…Phase 1

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell (BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell)

Relapsed/Refractory; Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

4 / 8 pages

← PreviousNext →